Literature DB >> 2974765

Presence of an IL-3-producing suppressor T cell resistant to cyclosporin A in the peripheral blood of patients with systemic lupus erythematosus.

A Vidaller, L Llorente, D Alarcón-Segovia.   

Abstract

We studied the effects of cyclosporin A (CYA) on the production of various lymphokines and on the suppressor functions of peripheral blood mononuclear cells (MNC) of ten untreated SLE patients. CYA was found to inhibit the production of IL-2 and of B cell stimulating factor (BSF) by both normal and SLE MNC but it did not alter the LPS-driven production of IL-1 by either of them. However, it did abrogate the spontaneous release of IL-1 by SLE monocytes. CYA strongly inhibited the production of IL-3-like activity by normal T cells, an effect noticed only on cells from 4 SLE patients, three of whom were in remission. Addition of CYA significantly increased suppressor cell function by cells from all SLE patients. T cell clones could be obtained from two of them by using CYA-conditioned medium containing IL-3. These clones were found to have strong suppressor capacity.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2974765      PMCID: PMC1541749     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  18 in total

1.  Partial purification of human lymphocyte-activating factor (LAF) by ultrafiltration and electrophoretic techniques.

Authors:  L B Lachman; M P Hacker; R E Handschumacher
Journal:  J Immunol       Date:  1977-12       Impact factor: 5.422

2.  Production of human immune interferon (Hu IFN-gamma) studied at the single cell level. Origin, evidence for spontaneous secretion and effect of cyclosporin A.

Authors:  R Palacios; O Martinez-Maza; M De Ley
Journal:  Eur J Immunol       Date:  1983-03       Impact factor: 5.532

3.  The 1982 revised criteria for the classification of systemic lupus erythematosus.

Authors:  E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester
Journal:  Arthritis Rheum       Date:  1982-11

4.  Decreased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus.

Authors:  J Alcocer-Varela; D Alarcón-Segovia
Journal:  J Clin Invest       Date:  1982-06       Impact factor: 14.808

5.  Relapse of systemic lupus erythematosus in a patient receiving cyclosporine A.

Authors:  D Makover; B Freundlich; R B Zurier
Journal:  J Rheumatol       Date:  1988-01       Impact factor: 4.666

6.  Stimulating and differentiation factors for human B lymphocytes in systemic lupus erythematosus.

Authors:  E Martinez-Cordero; J Alcocer-Varela; D Alarcon-Segovia
Journal:  Clin Exp Immunol       Date:  1986-09       Impact factor: 4.330

7.  Heterogeneity of the spontaneously expanded and mitogen-induced generation of suppressor cell function of T cells on B cells in systemic lupus erythematosus.

Authors:  A Ruiz-Arguelles; D Alarcón-Segovia; L Llorente; J A Del Giudice-Knipping
Journal:  Arthritis Rheum       Date:  1980-09

8.  Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2.

Authors:  D Bunjes; C Hardt; M Röllinghoff; H Wagner
Journal:  Eur J Immunol       Date:  1981-08       Impact factor: 5.532

9.  Deficiencies in suppressor T cell activity seen in patients with active systemic lupus erythematosus are due to the dilution of normally functioning suppressor T cells by nonsuppressor T cells.

Authors:  T Sakane; S Takada; N Suzuki; T Tsuchida; Y Murakawa; Y Ueda
Journal:  J Immunol       Date:  1986-12-15       Impact factor: 5.422

10.  The functional relationship of the interleukins.

Authors:  K A Smith; L B Lachman; J J Oppenheim; M F Favata
Journal:  J Exp Med       Date:  1980-06-01       Impact factor: 14.307

View more
  1 in total

1.  Aseptic necrosis at multiple localisations in a lupus patient with lymphoma.

Authors:  A Bazso; T Bazso; P Szodoray; G Poor; E Kiss
Journal:  Osteoporos Int       Date:  2013-12-03       Impact factor: 4.507

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.